Breaking News
Sort by:
Top Post
Roche’s Tecentriq Plus Avastin Reduced Risk of Cancer Returning in People with Certain Types of Adjuvant Liver Cancer in a Phase III Study
Roche has announced new data from the Phase III IMbrave050 study that show Tecentriq (atezolizumab) […]
SomaLogic Announces License Agreement with OncoHost for the Development of Precision Cancer Diagnostics
SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced it has signed a […]
RAD Adds Brain Tumor Technology to Portfolio
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a world-class developer of cutting-edge radiopharmaceutical products for […]
European Commission Approves Roche’s Tecentriq as Adjuvant Treatment for a Subset of People With Early-stage Non-small Cell Lung Cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) […]
European Commission Approves Roche’s First-in-class Bispecific Antibody Lunsumio for People With Relapsed or Refractory Follicular Lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional […]
Epic Sciences Raises $43M in First Close of Series F Financing to Advance Comprehensive Profiling for Metastatic Cancer Patients
Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $43 […]
Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma
Kite, a Gilead Company (Nasdaq: GILD), today announced longer-term follow-up results from two pivotal studies […]
New Novartis Data Show Piqray® Effectiveness Across Key Biomarkers in Patients With HR+/HER2- Metastatic Breast Cancer
Novartis today announced results of an exploratory retrospective biomarker analysis finding that different genetic mutation […]
Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and GO Therapeutics, Inc. (Co-Founder […]
Priothera Receives Fast Track Designation for Mocravimod in Combination with Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Post Remission Therapy of Acute Myeloid Leukemia (AML) Patients
Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound, […]
Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from the registration-enabling […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more